Shortages of medicines within the EU and the improved access to innovative medication across the Union, particularly in small markets such as Malta, were the main focus of discussions between Deputy Prime Minister and Minister for Health Chris Fearne and European Commissioner for Health and Food Safety, Stella Kyriakides, during her official visit to Malta.
Medicine shortages within the EU and improved access to innovative medication across the union, particularly in small markets such as Malta, were the main focus of discussions between Health Minister Chris Fearne and European Health Commissioner Stella Kyriakides.
European Commissioner for Health and Food Safety, Stella Kyriakides, along with Christopher Fearne, the Deputy Prime Minister and Minister for Health of Malta, visited the Medichem manufacturing sites as part of the Commissioner’s visit to Malta to speak at the Medicines for Europe Annual Conference. The conference has taken place from the 14th to the 16th of June 2023 and has been a platform for discussing policies and measures that will contribute to the improvement of patient health and the competitive pharmaceutical environment in Europe.
Adrian Van Der Hoven joins panelists elaborating on the EU Pharma Package and the potential showdown with the pharma sector and called Europe out for being late to the Artificial Intelligence party.
When Ignasi Biosca-Reig heard there were shortages of amoxicillin in Spain, he quickly added shifts at his drug company’s factories to boost production of the popular antibiotic. But a few extra shifts was as far as he could go.
The generics industry is urging EU and national governments to show “leadership” and take immediate action against rising inflation, which has resulted in drug shortages and has put patients in need to the test.
Can the European Union bring eye-wateringly expensive medicines to the poorest parts of Europe, find cures for untreatable diseases, and solve the problem of antimicrobial resistance, all with a stroke of its pen?
Victor Mendonça, chair of the Generic Market Access Committee at Medicines for Europe, outlines why patient access to medicines is at risk due to intense price pressure and unprecedented inflation and proposes ways to tackle this.